Loading stock data…
Moderna, Inc. (MRNA)
$54.07-2.95 (-5.17%)
Market ClosedLast close Jul 24
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Moderna, Inc. in the Healthcare sector is trading at $54.07 with a market capitalization of $18.7B. Wall Street consensus targets $49.37 (19 analysts), implying a -8.7% move over the next 12 months. The stock is currently 37% below its 52-week high of $85.60, remaining 22.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 12 is oversold, raising the odds of a near-term bounce. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -8.7% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 12) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $389.00M↓ | $676.00M↓ | $1.00B↑ | $137.00M↑ | $107.00M |
| Gross Profit | -$566.00M↓ | $224.00M↓ | $795.00M↑ | $18.00M↑ | $17.00M |
| Operating Income | -$1.39B↓ | -$857.00M↓ | -$260.00M↑ | -$907.00M↑ | -$1.05B |
| Net Income | -$1.34B↓ | -$826.00M↓ | -$200.00M↑ | -$825.00M↑ | -$971.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pand...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$18.72B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.12%
Volume
Today's trading volume
4.32M
Recent News
FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions
The days ahead pack several binary or near-binary catalysts for U.S. biotech and biopharma companies—decisions that could sharply reshape valuations overnight.
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dassault Systemes SE (DASTF) (H1 2026) Earnings Call Highlights: Strong Subscription Growth and ...
Despite challenges in life sciences and European automotive sectors, Dassault Systemes SE (DASTF) reports robust revenue growth and strategic advancements in AI and cloud solutions.
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?
With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.
Earnings Preview: What To Expect From Moderna’s Report
Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.